Prof. Dr. Christoph Driessen
Chefarzt Klinik für Medizinische Onkologie und Hämatologie, Kantonsspital St.Gallen
Stellvertretender Leiter Comprehensive Cancer Center Kantonsspital St.Gallen
Medizinische Onkologie und Hämatologie · Dept. I
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
Geurink P, Overkleeft H, Groll M, van der Stelt M, Driessen C, van der Marel G, Florea B, Mock E, Voges M, Blom A, de Bruin G, Gallastegui N, Mirabella A, van der Linden W, Kisselev A. Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem 2013; 56:1262-75.
28.01.2013Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites
28.01.2013J Med Chem 2013; 56:1262-75
Geurink Paul P, Overkleeft Herman S, Groll Michael, van der Stelt Mario, Driessen Christoph, van der Marel Gijs A, Florea Bogdan I, Mock Elliot D, Voges Mathias J, Blom Annet E M, de Bruin Gerjan, Gallastegui Nerea, Mirabella Anne C, van der Linden Wouter A, Kisselev Alexei F
Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides
Held S, Brossart P, Driessen C, Schild H, Kurts C, Bringmann A, von Schwarzenberg K, Rückrich T, Tenzer S, Duchardt K, Heine A. Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. Cancer Immunol Immunother 2012; 62:715-26.
25.11.2012Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides
25.11.2012Cancer Immunol Immunother 2012; 62:715-26
Held Stefanie Andrea Erika, Brossart Peter, Driessen Christoph, Schild Hansjörg, Kurts Christian, Bringmann Anita, von Schwarzenberg Karin, Rückrich Thomas, Tenzer Stefan, Duchardt Katharina Maria, Heine Annkristin
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
08.10.2012A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
08.10.2012Eur J Cancer 2012; 49:290-6
Gallerani Elisa, D'Incalci Maurizio, Sala Federica, Cereda Roberta, Marsoni Silvia, de Braud Filippo, Driessen Christoph, Böhm Steffen, Martinelli Giovanni, Delmonte Angelo, Hess Urs, Noberasco Cristina, Marangon Elena, Brunelli Dario, Zucchetti Massimo, Sessa Cristiana
Intravascular lymphoma mimicking cerebral stroke: report of two cases
Hundsberger T, Tettenborn B, von Moos R, Fournier J, Anliker M, Gähler A, Fretz C, Kleger G, Cogliatti S, Driessen C. Intravascular lymphoma mimicking cerebral stroke: report of two cases. Case Rep Neurol 2011; 3:278-283.
24.10.2011Intravascular lymphoma mimicking cerebral stroke: report of two cases
24.10.2011Case Rep Neurol 2011; 3:278-283
Hundsberger Thomas, Tettenborn Barbara, von Moos Roger, Fournier Jean-Yves, Anliker Mark, Gähler Anita, Fretz Christian, Kleger Gian-Reto, Cogliatti Sergio B., Driessen Christoph
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Engelhardt M, Straka C, Johnsen H, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Kropff M, Sezer O, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón J, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010; 51:2006-11.
31.08.2010European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
31.08.2010Leuk Lymphoma 2010; 51:2006-11
Engelhardt Monika, Straka Christian, Johnsen Hans E, Waage Anders, Boegsted Martin, Lokhorst Henk, Hájek Roman, Morgan Gareth, Boccadoro Mario, Ludwig Heinz, Cavo Michele, Polliack Aaron, Sonneveld Pieter, Einsele Hermann, Kropff Martin, Sezer Orhan, Udi Josefina, Kleber Martina, Spencer Andrew, Rocci Alberto, Knop Stefan, Bruno Benedetto, Bringhen Sara, Pérez-Simón José A, Zweegman Sonja, Driessen Christoph, Patriarca Francesca, Gramatzki Martin, Terpos Evangelos, Palumbo Antonio
Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines
Clerc J, Overkleeft H, Driessen C, Dudler R, Bachmann A, Huber R, Groll M, Kraus M, Florea B, Kaiser M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem : a European journal of chemical biology 2009; 10:2638-43.
02.11.2009Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines
02.11.2009Chembiochem : a European journal of chemical biology 2009; 10:2638-43
Clerc Jérôme, Overkleeft Herman S, Driessen Christoph, Dudler Robert, Bachmann André S, Huber Robert, Groll Michael, Kraus Marianne, Florea Bogdan I, Kaiser Markus
HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase
Harman A, Driessen C, Slobedman B, Stern J, Nasr N, Mercier S, Tang O, Turville S, Byth K, Bye C, Kraus M, Cunningham A. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood 2009; 114:85-94.
02.07.2009HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase
02.07.2009Blood 2009; 114:85-94
Harman Andrew N, Driessen Christoph, Slobedman Barry, Stern Josh L, Nasr Najla, Mercier Sarah K, Tang Owen, Turville Stuart G, Byth Karen, Bye Chris R, Kraus Marianne, Cunningham Anthony L
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft H, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009; 23:1098-105.
01.06.2009Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
01.06.2009Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009; 23:1098-105
Rückrich T, Kraus Marianne, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft H S, Kalbacher H, Driessen Christoph
Receptor-mediated targeting of cathepsins in professional antigen presenting cells
Hillaert U, Driessen C, van der Marel G, Ossendorp F, Van Calenbergh S, Kuiper J, Habets K, Saragliadis A, Saragliadis A, Florea B, Verdoes M, Overkleeft H. Receptor-mediated targeting of cathepsins in professional antigen presenting cells. Angewandte Chemie (International ed. in English) 2009; 48:1629-32.
01.01.2009Receptor-mediated targeting of cathepsins in professional antigen presenting cells
01.01.2009Angewandte Chemie (International ed. in English) 2009; 48:1629-32
Hillaert Ulrik, Driessen Christoph, van der Marel Gijsbert A, Ossendorp Ferry, Van Calenbergh Serge, Kuiper Johan, Habets Kim L L, Saragliadis Anastasios, Saragliadis Athanasios, Florea Bogdan I, Verdoes Martijn, Overkleeft Hermen S
Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels
Kessler T, Reich M, Jahn G, Tolosa E, Beck A, Kalbacher H, Overkleeft H, Schempp S, Driessen C. Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. The Journal of general virology 2008; 89:2427-36.
01.10.2008Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels
01.10.2008The Journal of general virology 2008; 89:2427-36
Kessler Tobias, Reich Michael, Jahn Gerhard, Tolosa Eva, Beck Alexander, Kalbacher Hubert, Overkleeft Herman, Schempp Susanne, Driessen Christoph
Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation
Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, Weissert R. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. European journal of immunology 2008; 38:2401-11.
01.09.2008Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation
01.09.2008European journal of immunology 2008; 38:2401-11
Fissolo Nicolas, Kraus Marianne, Reich Michael, Ayturan Miriam, Overkleeft Herman, Driessen Christoph, Weissert Robert
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
Kraus M, Hartmann J, Koscielniak E, Ovaa H, Overkleeft H, Rückrich T, Müller H, Gogel J, Malenke E, Driessen C. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Molecular cancer therapeutics 2008; 7:1940-8.
01.07.2008Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
01.07.2008Molecular cancer therapeutics 2008; 7:1940-8
Kraus Marianne, Hartmann Jörg Thomas, Koscielniak Ewa, Ovaa Huib, Overkleeft Herman, Rückrich Thomas, Müller Holger, Gogel Jeannette, Malenke Elke, Driessen Christoph
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
Horger M, Pereira P, Claussen C, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol 2008; 81:386-96.
01.05.2008Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
01.05.2008Br J Radiol 2008; 81:386-96
Horger Marius, Pereira Philippe, Claussen Claus Detlef, Kanz Lothar, Vonthein Reinhard, Denecke Barbara, Driessen Christoph
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Busse A, Kraus M, Na I, Rietz A, Scheibenbogen C, Driessen C, Blau I, Thiel E, Keilholz U. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008; 112:659-70.
01.02.2008Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
01.02.2008Cancer 2008; 112:659-70
Busse Antonia, Kraus Marianne, Na Il-Kang, Rietz Anika, Scheibenbogen Carmen, Driessen Christoph, Blau Igor Wolfgang, Thiel Eckhard, Keilholz Ulrich
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Schulz H, Engert A, Diehl V, Schnell R, Borchmann P, Rüdiger T, Driessen C, Elter T, Morschhauser F, Rehwald U, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-11.
01.01.2008Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
01.01.2008Blood 2008; 111:109-11
Schulz Holger, Engert Andreas, Diehl Volker, Schnell Roland, Borchmann Peter, Rüdiger Thomas, Driessen Christoph, Elter Thomas, Morschhauser Franck, Rehwald Ute, Reiser Marcel
A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A
Zaidi N, Burster T, Sommandas V, Herrmann T, Boehm B, Driessen C, Voelter W, Kalbacher H. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochemical and biophysical research communications 2007; 364:243-9.
14.12.2007A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A
14.12.2007Biochemical and biophysical research communications 2007; 364:243-9
Zaidi Nousheen, Burster Timo, Sommandas Vinod, Herrmann Timo, Boehm Bernhard O, Driessen Christoph, Voelter Wolfgang, Kalbacher Hubert
Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions
Burster T, Kalbacher H, Verhelst S, Weber E, Falk K, Rotzschke O, Dunn S, Boehm B, Marin-Esteban V, Driessen C. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions. Biochemical pharmacology 2007; 74:1514-23.
15.11.2007Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions
15.11.2007Biochemical pharmacology 2007; 74:1514-23
Burster Timo, Kalbacher Hubert, Verhelst Steven H L, Weber Ekkehard, Falk Kirsten, Rotzschke Olaf, Dunn Shannon, Boehm Bernhard O, Marin-Esteban Viviana, Driessen Christoph
A new approach for distinguishing cathepsin E and D activity in antigen-processing organelles
Zaidi N, Herrmann T, Baechle D, Schleicher S, Gogel J, Driessen C, Voelter W, Kalbacher H. A new approach for distinguishing cathepsin E and D activity in antigen-processing organelles. The FEBS journal 2007; 274:3138-49.
01.06.2007A new approach for distinguishing cathepsin E and D activity in antigen-processing organelles
01.06.2007The FEBS journal 2007; 274:3138-49
Zaidi Nousheen, Herrmann Timo, Baechle Daniel, Schleicher Sabine, Gogel Jeannette, Driessen Christoph, Voelter Wolfgang, Kalbacher Hubert
Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro
Burster T, Tolosa E, Overkleeft H, Kalbacher H, Youssef S, Boehm B, Falk K, Roetzschke O, Reich M, Baechle D, Øren A, Poeschel S, Beck A, Driessen C. Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro. Immunology 2007; 121:82-93.
01.05.2007Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro
01.05.2007Immunology 2007; 121:82-93
Burster Timo, Tolosa Eva, Overkleeft Herman, Kalbacher Hubert, Youssef Sawsan, Boehm Bernhard O, Falk Kirsten, Roetzschke Olaf, Reich Michael, Baechle Daniel, Øren Anita, Poeschel Simone, Beck Alexander, Driessen Christoph
The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.
15.04.2007The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
15.04.2007Cancer 2007; 109:1617-26
Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph